Mubadala has completed the sale of its minority stake in Arcadia Consumer Healthcare, drawing to a close a four-year investment alongside private equity firm Bansk Group.

The exit coincides with funds managed by Bansk acquiring full ownership of the US-based consumer healthcare platform. Financial terms of the transaction were not disclosed.

Arcadia has built a portfolio of over-the-counter medicines and wellness brands, including Nizoral, Colace, Senokot, CloSYS, Betadine, and Kaopectate. During Mubadala’s investment period, the company’s revenue tripled and profitability improved materially.

“It has been a privilege to partner with Bansk, Mike DeBiasi and the Arcadia team over the past four years,” Philip Yifei Bao, director of private equity at Mubadala, said in a statement. “We are incredibly proud to have supported the transformation of Arcadia into the leading North American consumer health and wellness platform.”

Bansk said Mubadala’s long-term approach helped accelerate Arcadia’s growth and integrate acquisitions including Avrio and CloSYS.

The deal marks another successful healthcare exit for Mubadala and underlines sustained private equity interest in consumer health platforms with resilient demand.

If you think we missed any important news, please do not hesitate to contact us at [email protected].

Can`t stop reading? Read more.